Supplementary Methods from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Authors
Jo Lynne Rokita (ORCID: https://orcid.org/0000-0003-2171-3627)
John M. Maris (ORCID: https://orcid.org/0000-0002-8088-7929)
Mark Gerelus (ORCID: https://orcid.org/0000-0001-8986-4523)
Esther R. Berko (ORCID: https://orcid.org/0000-0001-7181-1378)
Supplementary Methods from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Jo Lynne Rokita, John M. Maris, Mark Gerelus, Esther R. Berko et al.
Topics
Neuroblastoma Research and Treatments
article
Supplementary Methods from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Jo Lynne Rokita, John M. Maris, Mark Gerelus, Esther R. Berko, Smita Matkar, Yaël P. Mossé, Gabriela M. Witek, Timothy Joseph Stuhlmiller, Gary L. Johnson, Kateryna Krytska, Joshua R. Kalna, Alvin Farrel, Colleen E. Casey, Denis O. Okumu, Michael P. East, Steven Pastor, Khushbu Patel, Anne Kennedy